Exciting News for ATTR-CM Patients with BEYONTTRA™ Approval
BridgeBio Pharma, Inc. has achieved a significant milestone with the European Commission's approval of BEYONTTRA™ (acoramidis), which is now the first near-complete transthyretin (TTR) stabilizer approved for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM). This innovative treatment brings hope to patients suffering from this complex, progressive disease, characterized by heart failure.
Phase 3 Study Highlights
The approval is founded on compelling results from the Phase 3 ATTRibute-CM study, which showcased the rapid benefits of acoramidis. In a record-setting performance, patients experienced a significant reduction in cardiovascular-related hospitalizations within as little as three months compared to placebo, marking one of the swiftest positive outcomes in ATTR-CM research.
Key Results
The study results were impressive: a notable 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalizations was observed after 30 months. Moreover, patients receiving acoramidis saw a 50% reduction in the frequency of cardiovascular hospitalizations at the same time point. The findings underscore the potential of this treatment to profoundly alter the disease course for many individuals.
First of Its Kind Treatment
BEYONTTRA™ stands out as the first and only approved ATTR-CM therapy in both the U.S. and EU, carrying a label that specifies its ability to achieve near-complete stabilization of TTR (?90%). Recent studies suggest that maintaining higher TTR concentrations may correlate with a reduced risk of mortality, enhancing hope for long-term health in patients.
Collaboration with Bayer
BridgeBio has strategically aligned with Bayer, which will handle all commercial activities for acoramidis in the EU. Following the marketing authorization, Bayer is set to launch BEYONTTRA™ in the first half of the upcoming year, providing vital access for patients in need.
Financial Impact and Support
As part of the collaboration agreement, BridgeBio will receive a $75 million milestone payment along with a tiered royalty structure commencing in the low-thirties percentage on sales of BEYONTTRA™. This financial backing will support BridgeBio in expanding its mission to address genetic diseases and deliver innovative treatments.
Future Perspectives and Ongoing Reviews
Acoramidis is not only receiving attention in Europe; it is also currently under review by the Japanese Pharmaceuticals and Medical Devices Agency and the Brazilian Health Regulatory Agency. The attention this treatment is drawing across multiple regions highlights its promise as a transformative option for patients living with ATTR-CM.
Expert Insights
Dr. Marianna Fontana, a prominent Professor of Cardiology, emphasized the importance of this approval, noting that untreated ATTR-CM is often fatal. The data shows that acoramidis can significantly enhance survival and help patients manage this challenging condition. This sentiment is echoed by Dr. Jonathan Fox, BridgeBio's Cardiorenal Chief Medical Officer, who expressed gratitude to all the trial participants and medical professionals whose dedication made this approval possible.
About BEYONTTRA and BridgeBio
BEYONTTRA™ (acoramidis) functions as a selective, orally administered TTR stabilizer for treating wild-type or variant transthyretin amyloidosis in adult patients dealing with cardiomyopathy. Feedback from clinical trials indicates that BEYONTTRA™ is generally well-tolerated, with only mild side effects reported. This is an essential aspect in patient adherence to medication. BridgeBio Pharma, Inc., founded with a vision to develop pathways for transformative medicine, constantly strives to bring hope to patients with genetic conditions. Their commitment prioritizes innovative research and patients' health above all.
Frequently Asked Questions
What is BEYONTTRA™ used for?
BEYONTTRA™ is used to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM) in adult patients.
What results did the Phase 3 study show?
The Phase 3 study showed significant reductions in all-cause mortality and cardiovascular-related hospitalizations, with benefits observed as early as three months.
Who will commercialize BEYONTTRA™ in the EU?
Bayer will be responsible for the commercialization of BEYONTTRA™ in the European Union.
What is the future outlook for BEYONTTRA™?
The treatment is under review in both Japan and Brazil, indicating a positive trajectory for future availability.
What distinguishes acoramidis from other treatments?
Acoramidis is the first treatment with a label confirming near-complete TTR stabilization, offering patients a unique therapeutic option.
